medRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2024,
Volume and Issue:
unknown
Published: June 8, 2024
Background:
People
with
HIV
(PWH)
often
have
a
suboptimal
response
to
vaccines,
raising
concerns
about
the
efficacy
of
coronavirus
disease
2019
(COVID-19)
vaccines
in
this
population.
We
aimed
evaluate
humoral
immune
B.1
lineage
and
Omicron
variant
PWH
following
COVID-19
vaccination.
Methods:
conducted
prospective
study
on
19
who
received
two-dose
series
mRNA
vaccine
booster
six
months
later.
Participants
without
infection
were
included
as
healthy
control
(HC)
group.
The
(anti-SARS-CoV-2
S
IgG
levels
ability
block
ACE2-S
interaction)
against
both
original
was
measured
by
immunoassays.
Results:
very
strong
(GMFR
>8)
after
second
dose
>4)
for
variant.
found
similar
responses
between
HC
groups
doses
(q-value
>0.05).
generated
significantly
weaker
compared
<0.05).
However,
improved
dose,
although
inhibition
interaction
remained
PWH.
Conclusions:
variant,
individuals
infection.
our
data
suggest
need
improve
immunogenicity
update
new
variants
like
Omicron.
Vaccine X,
Journal Year:
2023,
Volume and Issue:
15, P. 100405 - 100405
Published: Nov. 8, 2023
The
negative
impact
of
vaccine
conspiracies
is
linked
with
health
behavior.
aim
the
current
study
was
to
examine
association
between
attitudes
toward
booster
COVID-19,
influenza,
and
monkeypox
(mpox)
vaccinations
post-COVID-19
side
effects,
conspiracies,
attitude
towards
mandatory
vaccination
among
nurses
physicians
in
Jordan.
International Journal of Environmental Research and Public Health,
Journal Year:
2023,
Volume and Issue:
20(4), P. 2951 - 2951
Published: Feb. 8, 2023
Our
study
aims
to
assess
the
uptake
of
COVID-19
vaccination
and
its
associated
factors
among
Chinese
college
students.
A
web-based
cross-sectional
was
conducted
from
18
May
17
June
2022.
total
3916
participants
were
included.
The
coverage
first
dose,
complete
booster
students
99.49%,
81.96%
79.25%,
respectively.
College
with
an
older
age
(AOR:
0.72,
95%
CI:
0.57–0.90),
non-medical
major
(0.47,
0.37–0.61)
studying
in
north-east
China
(0.35,
0.22–0.58)
less
likely
vaccination.
Individuals
who
female
(1.62,
1.35–1.94)
received
a
recombinant
subunit
vaccine
(8.05,
5.21–12.45)
more
Non-medical
(0.56,
0.43–0.73)
(0.28,
0.16–0.49)
receive
while
(1.51,
1.23–1.85)
had
higher
likelihood.
main
reason
for
being
unvaccinated
“contraindication”
(75.00%),
not
receiving
dose
“being
too
busy
attend
it”
(61.37%).
This
demonstrated
high
adherence
policy
Targeted
strategies
should
be
applied
remove
barriers
medRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2024,
Volume and Issue:
unknown
Published: June 8, 2024
Background:
People
with
HIV
(PWH)
often
have
a
suboptimal
response
to
vaccines,
raising
concerns
about
the
efficacy
of
coronavirus
disease
2019
(COVID-19)
vaccines
in
this
population.
We
aimed
evaluate
humoral
immune
B.1
lineage
and
Omicron
variant
PWH
following
COVID-19
vaccination.
Methods:
conducted
prospective
study
on
19
who
received
two-dose
series
mRNA
vaccine
booster
six
months
later.
Participants
without
infection
were
included
as
healthy
control
(HC)
group.
The
(anti-SARS-CoV-2
S
IgG
levels
ability
block
ACE2-S
interaction)
against
both
original
was
measured
by
immunoassays.
Results:
very
strong
(GMFR
>8)
after
second
dose
>4)
for
variant.
found
similar
responses
between
HC
groups
doses
(q-value
>0.05).
generated
significantly
weaker
compared
<0.05).
However,
improved
dose,
although
inhibition
interaction
remained
PWH.
Conclusions:
variant,
individuals
infection.
our
data
suggest
need
improve
immunogenicity
update
new
variants
like
Omicron.
